Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
REDWOOD CITY, Calif., Feb. 03, 2016 -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on February 1, 2016, the compensation committee of the company’s board of directors granted 10 new employees options to purchase an aggregate of 17,800 shares of the company’s common stock with a per share exercise price of $18.86, the closing trading price on the grant date, and 8,900 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, Veltassa™ (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
